TLD (Tenofovir DF 300 mg + Lamivudine 300 mg + Dolutegravir 50 mg) #
Recognized as a preferred first-line antiretroviral regimen, TLD combines two nucleos(t)ide reverse transcriptase inhibitors with an integrase strand transfer inhibitor to support durable viral suppression in the treatment of HIV-1 infection, in accordance with WHO and NACO guidelines.
Product Details
Therapeutic Class
Nucleos(t)ide Reverse Transcriptase Inhibitors (Tenofovir DF + Lamivudine)
HIV Integrase Strand Transfer Inhibitor (Dolutegravir)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
One tablet once daily, or as prescribed by a healthcare professional.
To be used strictly as part of an ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
*This combination is under patent protection in several markets. Supply, manufacture, or distribution is subject to applicable patent laws and local regulatory approvals.
Pack Size
30 Tablets
TLD (Tenofovir DF 300 mg + Lamivudine 300 mg + Dolutegravir 50 mg) #
Recognized as a preferred first-line antiretroviral regimen, TLD combines two nucleos(t)ide reverse transcriptase inhibitors with an integrase strand transfer inhibitor to support durable viral suppression in the treatment of HIV-1 infection, in accordance with WHO and NACO guidelines.
Product Details
Therapeutic Class
Nucleos(t)ide Reverse Transcriptase Inhibitors (Tenofovir DF + Lamivudine)
HIV Integrase Strand Transfer Inhibitor (Dolutegravir)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
One tablet once daily, or as prescribed by a healthcare professional.
To be used strictly as part of an ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
*This combination is under patent protection in several markets. Supply, manufacture, or distribution is subject to applicable patent laws and local regulatory approvals.
Pack Size
30 Tablets
TLD (Tenofovir DF 300 mg + Lamivudine 300 mg + Dolutegravir 50 mg) #
Recognized as a preferred first-line antiretroviral regimen, TLD combines two nucleos(t)ide reverse transcriptase inhibitors with an integrase strand transfer inhibitor to support durable viral suppression in the treatment of HIV-1 infection, in accordance with WHO and NACO guidelines.
Product Details
Therapeutic Class
Nucleos(t)ide Reverse Transcriptase Inhibitors (Tenofovir DF + Lamivudine)
HIV Integrase Strand Transfer Inhibitor (Dolutegravir)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
One tablet once daily, or as prescribed by a healthcare professional.
To be used strictly as part of an ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
*This combination is under patent protection in several markets. Supply, manufacture, or distribution is subject to applicable patent laws and local regulatory approvals.
Pack Size
30 Tablets